These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 6230369)

  • 21. Comparative activities of ciprofloxacin (Bay o 9867), norfloxacin, pipemidic acid, and nalidixic acid.
    Muytjens HL; van der Ros-van de Repe J; van Veldhuizen G
    Antimicrob Agents Chemother; 1983 Aug; 24(2):302-4. PubMed ID: 6227281
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Antimicrobial activity of carbapenem antibiotics against gram-negative bacilli].
    Kinoshita S; Kumagai S
    Jpn J Antibiot; 1998 Sep; 51(9):551-60. PubMed ID: 9846282
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Action of imipenem on Enterobacter cloacae].
    Donnio PY; Lebert P; Travert MF; Avril JL
    Pathol Biol (Paris); 1988 May; 36(5):456-9. PubMed ID: 3043343
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Postantibiotic effect of imipenem on Pseudomonas aeruginosa.
    Bustamante CI; Drusano GL; Tatem BA; Standiford HC
    Antimicrob Agents Chemother; 1984 Nov; 26(5):678-82. PubMed ID: 6440477
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative in vitro susceptibilities of anaerobic bacteria to cefmenoxime, cefotetan, and N-formimidoyl thienamycin.
    Owens WE; Finegold SM
    Antimicrob Agents Chemother; 1983 Apr; 23(4):626-9. PubMed ID: 6305265
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.
    Wise R; Andrews JM; Edwards LJ
    Antimicrob Agents Chemother; 1983 Apr; 23(4):559-64. PubMed ID: 6222695
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative in vitro activity of CGP 31608, a new penem antibiotic.
    Eliopoulos GM; Wennersten C; Reiszner E; Moellering RC
    Antimicrob Agents Chemother; 1987 Aug; 31(8):1188-93. PubMed ID: 3498437
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro antibacterial activity of norfloxacin (MK-0366, AM-715) and other agents against gastrointestinal tract pathogens.
    Shungu DL; Weinberg E; Gadebusch HH
    Antimicrob Agents Chemother; 1983 Jan; 23(1):86-90. PubMed ID: 6219622
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The in-vitro activity of ciprofloxacin compared with that of norfloxacin and nalidixic acid.
    King A; Shannon K; Phillips I
    J Antimicrob Chemother; 1984 Apr; 13(4):325-31. PubMed ID: 6233249
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A multiclinic randomized study of the comparative efficacy, safety and tolerance of imipenem/cilastatin and moxalactam.
    Calandra GB; Hesney M; Grad C
    Eur J Clin Microbiol; 1984 Oct; 3(5):478-87. PubMed ID: 6389126
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Occurrence of gram negative bacteria in midstream bladder urine and their sensitivity to quinoline derivatives.
    Esposito S; Galante D; Pennucci C; Barba D
    Microbiologica; 1985 Jul; 8(3):269-76. PubMed ID: 3162081
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new beta-lactams, aminoglycosides, and trimethoprim.
    Chin NX; Neu HC
    Antimicrob Agents Chemother; 1983 Nov; 24(5):754-63. PubMed ID: 6229216
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Comparative in vitro effect of 7 quinolones on Ureaplasma urealyticum].
    Cantet P; Renaudin H; Quentin C; Bebear C
    Pathol Biol (Paris); 1983 Jun; 31(6):501-3. PubMed ID: 6224125
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Structure-activity relationships in the quinolone group: antibacterial activity of two new compounds (author's transl)].
    Thibault M; Koumaré B; Soussy CJ; Duval J
    Ann Microbiol (Paris); 1981; 132(3):267-81. PubMed ID: 6457546
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.
    Stamm JM; Hanson CW; Chu DT; Bailer R; Vojtko C; Fernandes PB
    Antimicrob Agents Chemother; 1986 Feb; 29(2):193-200. PubMed ID: 3087274
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro antibacterial activity of imipenem in combination with newer quinolone derivatives.
    Kern W; Gulden H; Vanek E; Kurrle E
    Chemotherapy; 1988; 34(2):117-26. PubMed ID: 3164670
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antimicrobial activity of the new carbapenem biapenem compared to imipenem, meropenem and other broad-spectrum beta-lactam drugs.
    Sader HS; Jones RN
    Eur J Clin Microbiol Infect Dis; 1993 May; 12(5):384-91. PubMed ID: 8354307
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro activity of N-formimidoyl thienamycin, moxalactam, and other new beta-lactam agents against Bacteroides fragilis: contribution of beta-lactamase to resistance.
    Brown JE; Del Bene VE; Collins CD
    Antimicrob Agents Chemother; 1981 Feb; 19(2):248-52. PubMed ID: 6214986
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro activity of pefloxacin compared to that of quinolones and other antimicrobial agents.
    Neu HC; Chin NX; Labthavikul P; Saha G
    Chemioterapia; 1984 Aug; 3(4):235-41. PubMed ID: 6241847
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative in vitro activity of norfloxacin and four other chemotherapeutics against urinary gram-negative isolates.
    Esposito S; Galante D; Pennucci C; Barba D; Limauro D; Scioli C
    Chemioterapia; 1984 Jun; 3(3):196-9. PubMed ID: 6241506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.